Featured Publications
Journal of Clinical Investigation
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
Li D*, Geng K*, Hao Y*, Gu J*, Kumar S*, Olson AT, Kuismi CC, Kim HM, Pan Y, Sherman F, Williams AM, Li Y, Li F, Chen T, Thakurdin C, Ranieri M, Meynardie M, Levin DS, Stephens J, Chafitz A, Chen J, Donald-Paladino MS, Powell JM, Zhang Z-Y, Chen W, Ploszaj M, Han H, Gu S, Zhang T, Hu B, Nacev BA, Kaiza M, Berger AH, Wang X, Li J, Sun X, Liu Y, Zhang X, Bruno T, Gray NS, Nabet B#, Wong K-K#, Zhang H#. (2024).
ChemBioChem
Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity.
Koide E*, Mohardt ML*, Doctor ZM, Yang A, Hao M, Donovan KA, Kuismi CC, Nelson AJ, Abell K, Aguiar M, Che J, Stokes MP, Zhang T, Aguirre AJ, Fischer ES, Gray NS, Jiang B#, Nabet B#. (2023).
Nature Communications
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.
Nabet B*,#, Ferguson FM*, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, Robichaud A, Conway AS, Buckley DL, Mancias JD, Bradner JE, Stegmaier K, Gray NS#. (2020).
Nature Chemical Biology
The dTAG system for immediate and target-specific protein degradation.
Nabet B*, Roberts JM*, Buckley DL*, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong K-KK, Gray NS, Bradner JE. (2018).